01-01-1970 12:00 AM | Source: Reuters
India's Sun Pharma to acquire U.S.-based Concert for $576 million
Sun Pharmaceutical Industries Limited said on Thursday it will acquire U.S.-based Concert Pharmaceuticals for $576 million in cash to gain access to an experimental drug for treating patchy baldness.
Concert's lead candidate, deuruxolitinib, is being evaluated as a treatment for autoimmune condition alopecia areata, which results in patchy hair loss.
India's Sun Pharma said it will commence a tender offer to acquire Concert at $8 per share, a premium of 16% to the stock's last close.
Concert stockholders will also receive a contingent value right entitling them an additional amount of up to $3.50 per share of common stock in cash, contingent on sales milestones.
Latest News
Insurance Sector Update : Motor drags down overall g...
Sell Gold Below 72700 SL Above 72950 TGT 72400/72100...
Wipro shares nosedived over 9 pc after missed earnin...
Economic Survey links mental health disorders with '...
India's GDP growth for FY25 to surpass Economic Surv...
Evening Roundup : A Daily Report on Bullion Energy &...
FIIs stood as net buyers in equities as per July 22 ...
Union Budget: Experts urge government to remove 18 ...
Poonawalla Fincorp AUM up 52% YoY to Rs 26,972 crore...
Sensex ends lower ahead of Union Budget 2024-25